Cargando…
HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
SIMPLE SUMMARY: There are several types of uterine cancer. Two of the more rare types are uterine serous carcinoma and carcinosarcoma, which are both very aggressive forms. These rare, aggressive types often have mutations that allow them to be treated with specific therapies that are targeted. One...
Autores principales: | McNamara, Blair, Mutlu, Levent, Greenman, Michelle, Harold, Justin, Santin, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452357/ https://www.ncbi.nlm.nih.gov/pubmed/37627113 http://dx.doi.org/10.3390/cancers15164085 |
Ejemplares similares
-
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers
por: Bellone, Stefania, et al.
Publicado: (2023) -
Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023) -
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023) -
Which is worse: uterine papillary serous carcinomas or carcinosarcomas?
por: Song, Taejong, et al.
Publicado: (2011) -
Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
por: Lopez, Salvatore, et al.
Publicado: (2018)